1. Home
  2. TRST vs SGMT Comparison

TRST vs SGMT Comparison

Compare TRST & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TrustCo Bank Corp NY

TRST

TrustCo Bank Corp NY

N/A

Current Price

$57.67

Market Cap

858.9M

Sector

Finance

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$10.98

Market Cap

761.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TRST
SGMT
Founded
1902
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
858.9M
761.6M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
TRST
SGMT
Price
$57.67
$10.98
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
★ $27.91
AVG Volume (30 Days)
91.1K
★ 1.1M
Earning Date
10-21-2026
11-24-2026
Dividend Yield
★ 2.76%
N/A
EPS Growth
★ 26.46
N/A
EPS
★ 2.91
N/A
Revenue
N/A
★ $2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.90
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.60
$4.50
52 Week High
$59.96
$11.45

Technical Indicators

Market Signals
Indicator
TRST
SGMT
Relative Strength Index (RSI) 57.38 59.00
Support Level $55.29 $6.44
Resistance Level $59.41 $11.23
Average True Range (ATR) 1.21 0.66
MACD 0.16 0.16
Stochastic Oscillator 46.85 81.40

Price Performance

Historical Comparison
TRST
SGMT

About TRST TrustCo Bank Corp NY

Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: